New Paper Alert
Mazyar Shadman: Closing the CAR T-Cell Therapy Access Gap in Large B-Cell Lymphoma
Mazyar Shadman/fredhutch.org

Mazyar Shadman: Closing the CAR T-Cell Therapy Access Gap in Large B-Cell Lymphoma

Mazyar Shadman, Professor of Hematology and Oncology at Fred Hutch and University of Washington, shared on LinkedIn:

“Just published in Blood Advance: ‘CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States.’

Our findings confirm that CAR T-cell therapy remains significantly underutilized, with only ~15% of patients receiving CAR T.

We need to

  • continue generating data
  • raising awareness
  • working to improve access and utilization.

Thanks to all the authors and collaborators who contributed to this work Bristol Myers Squibb.”

Title: CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States

Authors: Mazyar Shadman, Loretta J. Nastoupil, Krish Patel, Manali Kamdar, Matthew A Lunning, Fei Fei Liu, Christine T. Fu, Michael Cantrell, Amit Goyal, Dwaipayan Mukherjee, Tara Graff

Read the full article.

You may also be interested in:

Francesco Maura: What Determines Long-Term Response to CD19 CAR-T in Large B-Cell Lymphoma?

Mazyar Shadman: Closing the CAR T-Cell Therapy Access Gap in Large B-Cell Lymphoma

Amit Goyal Bristol Myers Squibb cancer cancer care cancer treatment CAR T-cell therapy Christine T. Fu Dwaipayan Mukherjee Fei-Fei Liu Krish Patel Large B-Cell Lymphoma Loretta J. Nastoupil Manali Kamdar Matthew A Lunning Mazyar Shadman Michael Cantrell OncoDaily Oncology Tara Graff